Page last updated: 2024-11-06
4-benzoylbutyrate
Description
4-Benzoylbutyrate is a synthetic compound with various potential applications. It is primarily studied for its pharmacological effects, particularly in relation to its ability to inhibit histone deacetylases (HDACs). HDACs are enzymes that play a crucial role in regulating gene expression by removing acetyl groups from histone proteins. By inhibiting HDACs, 4-benzoylbutyrate can alter gene expression patterns, potentially leading to therapeutic benefits in various diseases. The synthesis of 4-benzoylbutyrate typically involves a multi-step process, often starting with a Friedel-Crafts acylation reaction to introduce the benzoyl group onto a butyrate derivative. The compound's effects on cellular processes have been investigated in numerous studies, suggesting its potential as an anti-cancer agent, neuroprotective agent, and modulator of inflammation. Researchers continue to explore the therapeutic potential of 4-benzoylbutyrate in various disease models, including cancer, Alzheimer's disease, and inflammatory disorders. '
4-benzoylbutyric acid: has antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 73914 |
| SCHEMBL ID | 503304 |
| MeSH ID | M0548799 |
Synonyms (55)
| Synonym |
|---|
| HMS1475G03 |
| 5-keto-5-phenyl-valeric acid |
| benzenepentanoic acid, .delta.-oxo- |
| nsc10139 |
| 1501-05-9 |
| nsc-10139 |
| 4-benzoylbutyric acid |
| IDI1_019805 |
| OPREA1_086414 |
| CHEMDIV3_000839 |
| AP-406/42754026 |
| 5-oxo-5-phenylpentanoic acid |
| EU-0001968 |
| 5-oxo-5-phenylvaleric acid, 96% |
| STK386172 |
| B2768 , |
| 5-oxo-5-phenylvaleric acid |
| inchi=1/c11h12o3/c12-10(7-4-8-11(13)14)9-5-2-1-3-6-9/h1-3,5-6h,4,7-8h2,(h,13,14) |
| shkwsbavrqzyle-uhfffaoysa- |
| BRD-K86245308-001-01-0 |
| AKOS000813948 |
| A809007 |
| 4-benzoyl-butyric acid |
| benzenepentanoic acid, delta-oxo- |
| 4-benzoylbutyrate |
| nsc 10139 |
| einecs 216-113-5 |
| unii-595cfd21ka |
| 595cfd21ka , |
| FT-0600844 |
| F0722-1840 |
| AB01332132-02 |
| 4-benzoylbutyric acid;4-benzoylbutanoic acid |
| SCHEMBL503304 |
| delta-oxobenzenepentanoic acid |
| 5-oxo-5-phenylpentanoic acid # |
| W-108078 |
| DTXSID50164469 |
| SR-01000403987-1 |
| CS-W004848 |
| mfcd00004411 |
| sr-01000403987 |
| SY023883 |
| 5-phenyl-5-oxopentanoic acid |
| .gamma.-benzoylbutyric acid |
| butyric acid, 4-benzoyl- |
| 4-benzoylbutanoic acid |
| .delta.-oxobenzenepentanoic acid |
| 5-phenyl-5-oxovaleric acid |
| Q63399605 |
| AMY10729 |
| STR04963 |
| NCGC00341423-01 |
| EN300-178724 |
| Z361415342 |
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6
| A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | | | |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.68
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.68 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.63 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |